The terms of the CVR payments reflect the parties' agreement over the sharing of potential economic upside benefits from certain future net sales of NORTHERA as described in the CVR agreement and do not necessarily reflect anticipated sales of the product. There can be no assurance such levels of net sales will occur or that any or all of the contingent payments will be made. Lundbeck intends to acquire any shares of Chelsea not tendered into the tender offer through a merger for the same per share consideration as will be payable in the tender offer. The merger will be effected as soon as possible after the closing of the tender offer. The transaction will allow Lundbeck to leverage its expertise in rare neurologic disorders in the US through the upcoming launch of NORTHERA, which was approved by the FDA on February 18, 2014 for the treatment of symptomatic neurogenic orthostatic hypotension (NOH).